Pharma major Zydus Lifesciences on Tuesday announced its biggest-ever share buyback worth Rs 1,100 crore at a buyback price of Rs 1,150 per share, offering nearly a 13% premium over the stock’s previous closing price.
Zydus Lifesciences’ board approved a plan to buy back up to 95.65 lakh shares, each with a face value of Re 1, representing 0.95% of the company’s paid-up equity share capital, for an aggregate amount not exceeding Rs 1,100 crore.
Zydus Lifesciences fixes record date for buyback
The buyback will be conducted via the tender route. The record date to determine shareholders’ eligibility for the buyback has been fixed as May 29. This means only shareholders holding the company’s shares in their demat accounts as of the record date will be eligible to tender shares in the offer.
Zydus Lifesciences’ board of directors also approved the formation of a buyback committee, which can increase the buyback price or reduce the number of shares to be bought back up to one day before the record date, without changing the overall buyback size.
Other details, including the entitlement ratio and whether the promoter and promoter group will participate in the buyback, will be disclosed later.
Zydus Lifesciences share buyback history
This follows Zydus Lifesciences’ Rs 600 crore share buyback conducted via the tender route at a price of Rs 1,005 per share. The buyback price implied a premium of nearly 9% over the stock’s trading level on the record date. Prior to that, the company had executed a Rs 750 crore share buyback in 2022.
Zydus Lifesciences shareholding pattern
Before the buyback announcement, the promoter and promoter group held nearly a 75% stake in Zydus Lifesciences as of May 15, 2026, while retail investors and mutual funds held around 5% each. Foreign portfolio investors owned nearly 7% of the company, while insurance companies held slightly over 6%.
Zydus Lifesciences Q4 results
Zydus Lifesciences reported a consolidated net profit of Rs 1,272.5 crore for the January-March quarter of FY26, marking a 9% increase from the Rs 1,171 crore profit reported in the corresponding quarter of the previous financial year.
The company’s revenue from operations rose more than 16% year-on-year to Rs 7,587 crore during the quarter under review, compared with Rs 6,528 crore in the year-ago period.
Along with the Q4 results and share buyback announcement, Zydus Lifesciences said its board has recommended a final dividend of Re 1 per share (100%) on a face value of Re 1 each, subject to shareholders’ approval at the company’s Annual General Meeting scheduled for August 11.
Zydus Lifesciences share price
Zydus Lifesciences shares closed 3% higher on Tuesday following the Q4 results and buyback announcement. The stock has gained more than 8% over the past week and 9% in the last month, while rising over 11% so far in 2026.
Over the longer term, the stock has delivered returns of 15% over one year, 106% over three years and more than 65% over five years.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
